Our preclinical study found that the combination of the PLK1 inhibitor volasertib with the EGFR-TKI osimertinib induced complete tumor regression in EGFR-mutant NSCLC xenograft models, with sustained effects observed even after treatment cessation. The gene discussed is PLK1; the disease is non-small cell lung carcinoma.